Principal investigator Alex Pollen, PhD, with his co-investigators and team of researchers. A UC San Francisco–led research team, supported by a $12.2 million grant from the California Institute for Regenerative Medicine (CIRM), is exploring potential gene therapy for treatments autism as well as other neuropsychiatric disorders such as schizophrenia, and bipolar disorder. The project is … Continue reading Exploring Gene Therapy Treatments for Autism
CIRM Funds new UCSD VERGE Center to Better Understand Schizophrenia and Autism
From top left to right: Anne Bang, PhD; Carrie Bearden, PhD; Eugene Yeo, PhD; Jonathan Sebat, PhD Bottom left to right: Alysson Moutri, PhD; Lilia Iakoucheva, PhD; Sébastien Jacquemont; Trey Ideker, PhD A team of UC San Diego researchers with support of a $12.5 million grant from the California Institute for Regenerative Medicine (CIRM) plans … Continue reading CIRM Funds new UCSD VERGE Center to Better Understand Schizophrenia and Autism
The Stem Cellar’s Most Read Blogs of 2024
2024 was a significant year for the California Institute for Regenerative Medicine (CIRM). We reached major milestones, celebrated our 20th anniversary, and introduced our Strategic Allocation Framework (SAF) impact goals. We did this all while continuing to fund innovative work in regenerative medicine. The Stem Cellar blog is where we share these stories, providing readers … Continue reading The Stem Cellar’s Most Read Blogs of 2024
Potential Gene Therapy for Children with ADA-SCID
Photo Courtesy of Andrea Fernandez de Soto Imagine stepping outside and facing life‑threatening danger. For children born with ADA‑SCID (adenosine deaminase severe combined immunodeficiency), this is daily life. Their immune systems are so weak that a cold or a scraped knee can cause a dangerous infection. Donald Kohn, MD, a leading researcher at the UCLA … Continue reading Potential Gene Therapy for Children with ADA-SCID
A Step Forward in the Fight Against Advanced Kidney Cancer
Photo Courtesy: Allogene Therapeutics Metastatic renal cell carcinoma (RCC) is an advanced kidney cancer with limited treatment options and a five‑year survival rate below 17%. With CIRM’s support, Allogene Therapeutics is developing ALLO‑316, an allogeneic CAR‑T cell therapy that targets CD70, a protein highly expressed on clear cell renal cell carcinoma (ccRCC) tumors. The approach … Continue reading A Step Forward in the Fight Against Advanced Kidney Cancer
Two CIRM-funded research projects receive RMAT designation from FDA
The U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to two research projects funded by the California Institute for Regenerative Medicine (CIRM). RMAT is a fast‑track designation that speeds the development, review, and potential approval of treatments for serious or life‑threatening diseases. The first RMAT designation went to a … Continue reading Two CIRM-funded research projects receive RMAT designation from FDA
Remembering CIRM board member and ALS patient advocate Fred Fisher
CIRM honors the contributions of Fred Fisher, MSW, LCSW, a dedicated member of our Independent Citizens’ Oversight Committee (ICOC) and a passionate patient advocate. Fred passed away in September. He joined the ICOC as the ALS patient advocate in June 2021 and served in many roles, including co‑chair of the Standards Working Group and member … Continue reading Remembering CIRM board member and ALS patient advocate Fred Fisher
Celebrating Two Decades of Progress with CIRM’s 2024 Annual Report
Celebrate with us our two decades of progress. Our 2024 Annual Report highlights 20 years of advancing regenerative medicine. For twenty years, CIRM has pushed the boundaries of stem cell and gene therapy. We have funded more than 109 clinical trials and built the infrastructure that drives research and development. Our work has fueled innovation, … Continue reading Celebrating Two Decades of Progress with CIRM’s 2024 Annual Report
CIRM Welcomes New Board Members
The California Institute for Regenerative Medicine (CIRM) welcomes a distinguished group of new board members and alternates, each bringing a wealth of experience and leadership in healthcare, research, and innovation. Joyce A. Sackey, MD, FACP Dr. Sackey joins CIRM as an alternate for Linda Boxer. As the inaugural Chief Equity, Diversity, and Inclusion Officer at … Continue reading CIRM Welcomes New Board Members
UCLA researchers exploring ways to prevent heart failure after heart attacks
ENPP1 is expressed in the region of scarring after injury to the heart. Cardiac muscle shown in red and ENPP1 in green demonstrates expression of ENPP1 in the region of scar formation. | Credit: Arjun Deb Lab/UCLA At the California Institute for Regenerative Medicine (CIRM), we support cardiovascular research from Discovery through Clinical to advance … Continue reading UCLA researchers exploring ways to prevent heart failure after heart attacks